Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 3/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2669557 | 0.92 | GCK (0.35) | GCKGPR119GRM5MEN1KMT2A | |
| SCHEMBL2074230 | 0.92 | GCK (0.35) | GCKGPR119GRM5MEN1KMT2A | |
| SCHEMBL2074483 | 0.85 | GCK (0.38) | GCKKCNH2 | |
| SCHEMBL2074125 | 0.84 | GCK (0.43) | GCKKCNH2 | |
| SCHEMBL2074415 | 0.84 | GCK (0.42) | GCKKCNH2 | |
| SCHEMBL2669717 | 0.80 | GCK (0.41) | GCKGPR119KCNH2 | |
| SCHEMBL2669546 | 0.78 | GCK (0.39) | GCKPPARGGRM5MEN1KMT2A | |
| SCHEMBL1775637 | 0.74 | GCK (0.44) | GCKKCNH2 | |
| SCHEMBL2074591 | 0.74 | GCK (0.48) | GCKMEN1KMT2AKCNH2 | |
| SCHEMBL2669612 | 0.73 | GCK (0.41) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902200-B2 | 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902200-B2 | 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| US-7902200-B2 | 3-[6-(Azetidine-1-carbonyl)pyridin-3-yl]oxy-5-[(3S)-1-methyl-2-oxo-pyrrolidin-3-yl]oxy-N-(5-methylpyrazin-2-yl)benzamide; activates glucokinase leading to decreased glucose threshold for insulin secretion and lowering of blood glucose by increasing hepatic glucose uptake; antidiabetic agents; obesity | ASTRAZENECA AB (SE) | 2011-03-08 | — | — | US | disclosed |
| EP-2086964-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | Astra Zeneca AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171734-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050101-A2 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS USEFUL IN THE TREATMENT OF A DISEASE MEDIATED THROUGH GLK | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171734-A1 | CHEMICAL COMPOUNDS | HK1, GCKR, GCK | GCK 3/4885GPR119 34/4885PPARG 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.